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Duchenne muscular dystrophy (DMD) is a muscular dystrophy with high incidence of learning and 
behavioural problems and is associated with neurodevelopmental disorders. To gain more insights 
into the role of dystrophin in this cognitive phenotype, we performed a comprehensive analysis 
of the expression patterns of dystrophin isoforms across human brain development, using unique 
transcriptomic data from Allen Human Brain and BrainSpan atlases. Dystrophin isoforms show 
large changes in expression through life with pronounced differences between the foetal and adult 
human brain. The Dp140 isoform was expressed in the cerebral cortex only in foetal life stages, 
while in the cerebellum it was also expressed postnatally. The Purkinje isoform Dp427p was virtually 
absent. The expression of dystrophin isoforms was significantly associated with genes implicated 
in neurodevelopmental disorders, like autism spectrum disorders or attention-deficit hyper-activity 
disorders, which are known to be associated to DMD. We also identified relevant functional associations 
of the different isoforms, like an association with axon guidance or neuron differentiation during early 
development. Our results point to the crucial role of several dystrophin isoforms in the development 
and function of the human brain.
Duchenne (DMD) and Becker (BMD) muscular dystrophies are X-linked genetic neuromuscular disorders char-
acterized by severe and progressive muscle weakness. Mutations in the DMD gene result in absent/non-functional 
muscle dystrophin protein in DMD and shortened/partially functional protein in BMD.
In addition to skeletal muscle pathology, DMD is characterized by cognitive and behavioural problems with 
30% of boys with DMD showing cognitive impairment (IQ < 70)1 and 40% having reading deficits similar to those 
observed in patients with phonological dyslexia2–4. Moreover, there is a higher incidence of attention-deficit/
hyperactivity disorder (ADHD) (32%), anxiety disorder (27%), autism spectrum disorders (ASD) (15%), epilepsy 
(6.3%), and obsessive-compulsive disorder (OCD) (4.8%) in patients with DMD5–7. The progressive nature of the 
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muscle pathology is a hallmark of the disease. Unfortunately, there are no longitudinal studies that investigate 
whether the cognitive pathology in DMD is progressive. Developmental delay was reported below the age of 
four and more cerebral atrophy was seen in men with DMD compared to boys, which may indicate progression 
with age8,9. However, normalization of IQ values in older patients has also been suggested1. In BMD patients, fre-
quencies of learning difficulties or comorbidity with neurodevelopmental disorders have not been systematically 
reviewed. However, one report highlights a small group of relatively young patients, with spelling, arithmetic, 
reading difficulties, as well as behavioural problems and an earlier report had shown occurrence of epilepsy 
despite absent deviations from full scale IQ (FSIQ) distributions10,11. Caution is warranted, however, when pro-
jecting these results to the general BMD population.
The DMD gene contains at least seven independent, tissue-specific promoters and two polyA-addition sites, 
producing several isoforms that are named to reflect their length and splicing patterns (Fig. 1). The localization 
and function of the full-length muscle isoform Dp427m is well characterized both in humans and animal models. 
It is a crucial component of the dystrophin-glycoprotein complex (DGC), which bridges the inner cytoskeleton 
and the extracellular matrix providing structural stability to muscle fibers12,13. However, information on brain 
dystrophin is almost solely derived from animal models and cell culture studies, with only a few case studies in 
man14,15. It is believed that the cortical isoform Dp427c is predominantly expressed in neurons of the cortex and 
the CA regions of the hippocampus16,17. The Purkinje isoform Dp427p has two variants which are reported to be 
expressed in cerebellar Purkinje cells18. The shorter Dp260 and Dp116 isoforms are expressed primarily in the 
retina and the peripheral nerve, respectively19,20. There is very limited information on the sites of expression of 
the Dp140 isoform and its splice variants. A study of one 3.5 month old foetus and one 60 year old brain suggested 
that the Dp140 isoform is predominantly expressed during foetal life stages21. Finally, the Dp71 isoform is ubiq-
uitously expressed, with higher levels in the central nervous system (CNS)22,23.
The risk of cognitive impairment in DMD has been associated with the location of mutations within the DMD 
gene resulting in the absence of specific dystrophin isoforms. FSIQ scores correlate with the number of isoforms 
missing. Patients missing all isoforms due to mutations in the distal part of the gene have the lowest scores, 
whereas patients missing only the full-length isoform have the highest scores24. Moreover, patients lacking Dp140 
isoforms performed worse on all neuropsychological tests (general cognitive abilities, verbal memory, attention 
and executive functions) compared to those with preserved Dp14025. The relationship between the isoforms that 
are affected and the cognitive profile is further supported by the higher incidence of neurodevelopmental disor-
ders in patients missing Dp140 compared to patients missing only Dp4275,26. This group distinction was already 
detectable below the age of four, as assessed with developmental quotients8. Finally, imaging has shown reduced 
grey matter volume and altered white matter microstructure compared to age-matched healthy controls, which 
was also more profound in patients missing Dp14027.
Figure 1. Human dystrophin isoforms. Dystrophin isoforms derived from the DMD gene located on the X 
chromosome (GRCh37.p13, RefSeq Release 74: NG_012232.1). The vertical green dashes indicate individual 
exons. The full-length dystrophins (Dp427) have 79 exons, with isoforms starting at unique first exons. For 
some isoforms, multiple splice variants have been identified (indicated on the right-hand side). The shorter 
isoforms (relative to the full-length isoforms Dp427) have unique first exons (i.e. not included in any other 
isoform), with the exception of Dp71 and Dp40 which share a first exon but use alternative polyadenylation 
sites. The red boxes indicate the position of the promoter region of each isoform. The second exon of 
Dp427c,m,p was used to represent the full-length dystrophin as a group (indicated by a purple box). This figure 
was generated using the NCBI’s Sequence Viewer.
www.nature.com/scientificreports/
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Despite this mounting evidence of the association between the absence of shorter dystrophin isoforms and 
higher incidence of learning and behavioural disabilities, the aetiology of the CNS pathology in DMD and BMD 
remains elusive. In this study, we provide detailed analysis of the spatial and temporal expression patterns of the 
dystrophin isoforms in the pathology-free adult and developing human brain. Using co-expression analysis, we 
characterize the functional role of the dystrophin isoforms as well as their relationships to other neurological 
disorders across brain development.
Results
Differential dystrophin isoform expression during brain development. We used the BrainSpan 
atlas of the developing human brain transcriptome28 to assess the dystrophin isoform expression throughout 
development. The BrainSpan atlas provides RNA-sequencing expression profiling of 16 brain structures from 42 
donor brains spanning early pre-natal development (8 weeks post-conception) to adulthood (40 years of age). 
In order to assess the expression of the different dystrophin isoforms, we used the expression of the unique first 
exons of Dp427p, Dp427c, Dp427m, Dp260, Dp140, Dp116 and the shared first exon of Dp71 and Dp40 (Fig. 2). 
We grouped the donors into 10 developmental stages (Supplementary Table 1). Figure 2 shows the expression 
of all exons within the DMD gene, across different brain regions and through development. The expression of 
Dp427c, and Dp427m is low during foetal development, shows a slight increase around the age of two, and is 
low throughout middle adulthood. This pattern is consistent across the different brain regions, though more 
prominent in the cerebral cortex when assessing Dp427 exon two, which is shared between Dp427p, Dp427c and 
Dp427m (Fig. 2B–D).
In contrast to previous reports18,29, the Purkinje isoform Dp427p was virtually absent in the brain throughout 
development, with expression levels even lower than muscle dystrophin Dp427m. To verify that Dp427p is indeed 
expressed in mouse, but not in human brain, we analysed the expression of Dp427p in cerebellum and cerebral 
cortex samples from control adult human brain (provided by the Netherlands Brain Bank) using quantitative 
polymerase chain reaction (qPCR). Indeed, we did not observe Dp427p expression in the human cerebral cortex 
and also not in the cerebellum, where the Purkinje neurons are located (Supplementary Figure 1). Yet in line 
with previous studies30,31, Dp427p was expressed in the mouse cerebellum and not in the mouse cerebral cortex 
Figure 2. Dystrophin isoforms expression across brain development. (A) Dystrophin exons expression 
throughout brain development. The isoform unique first exons are indicated on top of the heatmap. The 
developmental stages are indicated on the left in post-conceptual weeks and months or years after birth. The 
BrainSpan atlas exon number is indicated below the heatmap together with the Dp427m exon numbering 
for reference. Bars below the heatmap indicate the different isoform groups. The grey bars corresponding to 
Dp427c,m,p are grouped together using exon 2 in further analysis (blue). The grey bars corresponding to 
Dp260 and Dp116 are expressed in the retina and peripheral nerves and are excluded from further analysis. 
The first exon of Dp140 (green) and Dp71 + Dp40 (orange) is used for further analysis. Boxes with a red ‘X’ 
indicate exons that are not part of the transcript. Expression values are presented as log2(RPKM). Brain region 
specific expression across development is shown for the cerebral cortex (B), hippocampus (C), amygdala (D) 
and cerebellum (E) of Dp427 (2nd exon), Dp140 (1st exon) and Dp71 + Dp40 (1st exon). PCW: post-conception 
week, Mon: months, Yrs: years.
www.nature.com/scientificreports/
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(Supplementary Figure 1). This sharp contrast in Dp427p expression in the cerebellum suggests a different role 
for Dp427p in human than in mouse.
As expected, the samples representing retinal Dp260 and peripheral nerve Dp116 have virtually no expression 
in the brain (their unique first exons are not expressed). By contrast, Dp140 is clearly expressed in the foetal brain, 
with high expression in the early to mid-foetal stages, but very low expression from the late foetal stage onwards. 
Nevertheless, Dp140 is still expressed in the cerebellum and cerebral cortex at middle adulthood (n = 3), which 
has never been reported before (Fig. 2E). To verify that Dp140 is indeed expressed in the adult cerebral cortex 
and cerebellum, we analysed the expression of Dp140 as described above for Dp427p. Results confirm expression 
on Dp140 in the adult human cerebral cortex, as well as much higher expression in the adult human cerebellum 
(Supplementary Figure 1).
The Dp71+Dp40 expression is high during foetal stages and remains high after birth and later in life showing 
little regional specificity, in line with earlier reports indicating ubiquitous expression14,32. This is further sup-
ported by qPCR results showing comparable Dp71 expression levels in the cortex and cerebellum (Supplementary 
Figure 1).
DMD expression in the adult human brain is high in the hippocampus and amygdala but low 
in the cerebellum relative to the brain average expression. To analyse the spatial distribution of 
DMD gene expression across the adult brain, we used the Allen Human Brain Atlas (AHBA), which has a much 
higher resolution than the BrainSpan atlas but lacks the temporal dimension. The AHBA provides microarray 
gene expression data from hundreds of samples extracted from six adult human brains, allowing detailed analysis 
of the regional expression of genes across the human brain. However, as oligo-dT primers were used for sample 
preparation, which capture the distal part of the gene, it is not possible to distinguish between different isoforms, 
nor is exon specific data available.
Relative to the average expression levels across the six donors, the highest expression levels of DMD were 
found in the hippocampus and amygdala (Fig. 3). Within the hippocampus, expression was highest in the CA4 
region which is a small region in between CA3 and the dentate gyrus, and lowest in the CA2 region (Fig. 3A, 
Supplementary Table 2). The expression of DMD in the amygdala was highest in the basolateral complex (La, BL 
and BM), the input side of the amygdala that receives information from the prefrontal cortex, which is implicated 
in complex behaviour. Relatively low DMD expression was found on the output side with the central nucleus 
which connects with the brainstem and pons. Of the basolateral complex, highest DMD expression was found in 
the lateral nucleus which receives information from the neocortex, thalamus and hippocampus.
Animal studies have thus far consistently shown high dystrophin expression in the cerebellum33,34. 
Surprisingly, the lowest levels of DMD expression in the human brain were found in the cerebellum and the 
Figure 3. DMD gene expression across the adult human brain. DMD expression in the adult human brain at 
high spatial resolution averaged from six adult donors (five males and one female; mean age 42 years). Data 
is shown relative to the average expression across the whole brain (z-score normalization). (A) The spatial 
distribution is highlighted in three cross-sections of the brain showing the high sub-structural expression in 
the amygdala and hippocampus in contrast to the low expression throughout the cerebellum. (B) The brain was 
subdivided into 22 non-overlapping anatomical regions. For each region, the average expression in each of the 
donors was calculated separately (after z-score normalization) and all six average values are shown in a boxplot. 
The number of samples are indicated on the right. Significantly higher expression was found in the subthalamus, 
amygdala, parahippocampus and hippocampal formation. Significantly lower expression was found in the 
cerebellum and pons (Mann-Whitney U-test; *P < 0.05, **P < 0.01, ***P < 0.001). Full structure names for the 
indicated acronyms can be found in the Materials and Methods.
www.nature.com/scientificreports/
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pons (Fig. 3B). Within the cerebellum, DMD expression was lowest in the globose (GL), fastigial (Fas) and den-
tate nuclei (DN) which receive inhibitory (GABAergic) input from Purkinje cells and excitatory (glutamatergic) 
inputs from mossy fibres and climbing fibre pathways. Second lowest expression was located in the regions asso-
ciated with working memory, in the biventral lobule (Bl). The regions implicated in timing and coordination as 
well as attention through the prefrontal cortex, in the tonsilla (TO) and semilunal lobule (SL) were third lowest.
Activity of transcription start sites in the DMD gene confirm expression observations. Gene 
expression is regulated by multiple factors that integrate at transcription start sites (TSSs) to control the transcrip-
tion of target genes in a cell-specific manner35. To better characterize the activity of the dystrophin transcripts 
across different tissues and cell-types, we analysed TSS usage within the DMD gene across different brain regions. 
Genome-wide TSS usage has been detected across many human cell-types in the FANTOM5 consortium data set 
(using cap analysis of gene expression; CAGE)36,37 and by the Roadmap Epigenomic Consortium using chromatin 
markers specific to TSSs38.
Using the FANTOM5 data, we mapped the usage of TSSs from tissue samples of the amygdala, hippocampus, 
cerebellum and cerebral cortex based on the TSS expression in the adult human brain (Fig. 4). In total, there 
were 25 TSSs within a window of 1 kb of the first exons of Dp427c, Dp427m, Dp427p, Dp260, Dp140, Dp116, 
and Dp70 + Dp41 (Supplementary Table 3). Consistent with our findings from the BrainSpan data and the qPCR 
experiment (Fig. 2 and Supplementary Figure 1), the TSSs of the Purkinje isoform were not expressed in any of 
the samples analysed. Similarly, we did not observe expression of the TSSs of Dp260 and Dp116. In addition, the 
expression of the TSSs of Dp427c was highest in the amygdala and hippocampus, in line with the observations 
from the AHBA analysis (Fig. 3). The short isoforms Dp71 + Dp40 were consistently expressed across the brain 
with lower expression in the cerebellum, in line with results from the BrainSpan analysis (Fig. 2A). The TSSs of 
Dp140 were expressed throughout the adult brain with higher expression in the cerebellum compared to the rest 
of the brain. The higher expression in the cerebellum is in line with the BrainSpan data (Fig. 2E). In contrast to the 
low expression levels observed after birth in the BrainSpan data, the expression levels of Dp140 TSSs were high 
in the cerebral cortex, hippocampus and amygdala of the adult brain. However, this matches our results from the 
Figure 4. DMD transcription start sites. Genome browser view of the different TSSs within the DMD gene. 
Active TSS state based on histone markers within the DMD gene are shown for 23 samples including foetal and 
adult brain, muscle, heart, liver and kidney. See Materials and Methods for detailed sample information. Red 
bars indicate an active TSS state as defined by the Roadmap Epigenomic Consortium38. The bottom eight tracks 
show the TSS activity (blue bars) within the first exons of the different isoforms captured by CAGE sequencing 
from the FANTOM5 project36,37. All the active TSSs have been highlighted by zooming in on the first exons 
of the different isoform groups, from left to right: Dp71 + Dp40, Dp140, and Dp427. Note the absence of any 
TSS activity or epigenetic markers for Dp427p. Data is aligned to the human reference genome (GRCh37) and 
RefSeq transcripts are shown at the top. Data is plotted using the WashU Epigenome Browser71.
www.nature.com/scientificreports/
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qPCR analysis of the adult cerebral cortex and cerebellum (Supplementary Figure 1). Finally, the expression of the 
TSSs of the muscle isoform (Dp427m) was low across the brain except in the cerebellum.
To further investigate TSS usage within the DMD gene, we used the data from the Roadmap Epigenomic 
Consortium38 to identify TSSs based on their chromatin signatures. We analysed the chromatin signatures (i.e. 
chromatin states) across the DMD gene, focusing on active TSS, in adult and foetal brain samples as well as 
samples from the muscle, heart, liver, aorta, and kidney (see Materials and Methods for a full list of samples). 
In general, brain samples showed high TSS activity for the Dp140 and Dp71 + Dp40 isoform groups (Fig. 4), 
while the muscle and heart samples showed high TSS activity for the Dp427 isoforms group. The foetal brain 
samples showed active TSS at the first exon of the Dp140 isoform but no active TSS for the Dp71 + Dp40 isoform, 
supporting the expression patterns shown in Fig. 2. The Dp140 isoform contained active TSS markers in the 
Neurospheres Cortex Derived, Angular Gyrus, Germinal Matrix and Mid Frontal Lobe samples and no active TSS 
in the Substania Nigra, Anterior Caudate, Cingulate Gyrus, and Inferior Temporal Lobe samples.
Dystrophin isoforms are significantly co-expressed with genes implicated in neurodevelop-
mental disorders. To get more insight into the functional role of dystrophin throughout human brain 
development and its association to other neurodevelopmental disorders, we analysed the spatial and temporal 
expression pattern relationships of the DMD gene and the different dystrophin isoforms. Co-expression anal-
ysis is a well-established approach to infer functional associations of genes using high-throughput expression 
data based on the ‘guilt by association’ principle39. First, we ranked all genes based on the correlation of their 
expression pattern to the DMD gene in the AHBA and to the three dystrophin isoform groups (Dp427, Dp140 
and Dp71 + Dp40) in the BrainSpan atlas, resulting in four ranked gene lists (Supplementary Table 4). Next, we 
tested whether genes related to five disorders with high incidence in DMD patients (ASD, intellectual disability 
(ID), ADD, OCD, and dyslexia; Supplementary Table 5) are overrepresented among genes which are strongly 
co-expressed with DMD and the three isoforms (Fig. 5).
Genes associated with ASD and ID were significantly co-expressed with dystrophin expression patterns 
for both the full-length and shorter isoforms, especially Dp140 (FDR-corrected P = 5.66 × 10−4; one-sided 
Mann-Whitney U-Test; Fig. 5). In addition, ADD- and OCD-related genes were significantly co-expressed 
with Dp427 (FDR-corrected P = 4.3 × 10−4; one-sided Mann-Whitney U-Test). The expression pattern of 
dyslexia-related genes followed DMD expression in the adult brain, as well as Dp427 and Dp71 + Dp40 expres-
sion in the developing brain (FDR-corrected P = 2.98 × 10−3; one-sided Mann-Whitney U-Test).
To assess the strength of the connections between the top 25 of DMD associated genes, we mapped these 
based on their spatial and temporal co-expression patterns with Dp427, Dp140 and Dp71 + Dp40 in the devel-
oping human brain to a co-expression network. We combined this with the individual disease associations from 
DisGeNET40 to get an insight into the disease associations without prior selection based on previously reported 
co-occurrence in DMD (Fig. 6). The Dp140 network shows a stronger co-expression between genes compared to 
the networks of Dp427 and Dp71 + Dp40. The overlaid disease annotations show strong co-expression between 
dystrophin isoforms and other diseases such as epilepsy, mental retardation, obesity, nervous system malfor-
mation, neurodevelopmental disorders and cardiovascular problems. These spatial and temporal co-expression 
relationships point toward a functional association between DMD and genes related to these disorders.
To get an insight into the functional role of dystrophin throughout brain development, we assessed genes with 
strong co-expression to the three different dystrophin isoform groups for enrichment in gene ontology (GO) 
terms (Fig. 6, Supplementary Table 6). The molecular function associated to Dp427 was channel activity and 
transmembrane transporter activity. This matched with the biological process of transmembrane transport and 
synaptic transmission. The cellular component associated with Dp427 was the neuron part and more specifically 
the synaptic membrane. Finally, the phenotype associations were abnormal synaptic transmission and abnormal 
nervous system physiology.
Genes co-expressed with Dp140 were enriched in GO-terms related to early neurodevelopment via regulation 
of neuron differentiation and neuron projection morphogenesis as well as chromatin modification. The cellular 
component was the main axon and the top phenotype associations were abnormal nervous system tract morphol-
ogy and abnormal corpus callosum morphology.
Figure 5. Genes co-expressed with dystrophin isoforms are enriched in disease-related genes. Genes co-
expressed with DMD gene across the adult human brain as well as the dystrophin isoforms across brain 
development (rows) are analysed for enrichment in genes harbouring rare de novo variants in ASD and ID 
probands, a curated set of ASD risk genes (SFARI ASD), ADD-, OCD-, and dyslexia-related genes. Heatmap 
colours correspond to −log10(FDR-corrected P-value). All enrichment values for the lists enriched at P < 0.05 
(one-sided Mann-Whitney U-test; FDR-corrected) are shown.
www.nature.com/scientificreports/
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Finally, genes co-expressed with Dp71 + Dp40 were enriched in terms related to receptor binding as well as 
vascular development. The cellular component was the cell surface interacting with the extracellular matrix and 
the actin cytoskeleton and the top phenotype was abnormality of the cerebral vasculature.
Discussion
We provide a comprehensive study of the expression of dystrophin isoforms in healthy human brain across ana-
tomical regions and developmental stages. The detailed analysis of the expression patterns of the dystrophin 
isoforms and their spatial and temporal co-expression relationships provide a better understanding of the role of 
dystrophin in the development and function of the human brain.
The full-length isoforms Dp427c and even Dp427m show very low yet detectable expression throughout 
human development, confirming earlier reports17,41. However, the Purkinje isoform (Dp427p) showed almost no 
expression in the developing human brain data which is in contrast to an earlier study by Gorecki et al.29 which 
established the Purkinje specificity of Dp427p by showing its expression in the mouse cerebellum. A later report 
by Holder et al.18 showed expression of Dp427p in one adult cortical sample and no expression signal in a 20-week 
old foetal brain sample using PCR. To further confirm our findings from the BrainSpan atlas, we validated the 
absence of Dp427p expression from adult human and mouse cerebral cortex and cerebellar samples using qPCR 
and by interrogating TSS usage information from the FANTOM5 project. These results illustrate discrepancies in 
dystrophin isoforms expression between human and mouse brains and highlight the importance of comprehen-
sive maps of expression in mouse and human brains for better translation between animal experiments to human 
conditions in which the DMD gene is implicated. It also means that results from studies specifically assessing the 
expression on Dp427p in mice may need to be reinterpreted30,34. Advances in single-cell RNA sequencing have 
made it possible to quantify gene expression levels in individual cells from different brain regions42,43. Mapping 
the expression of dystrophin isoforms in individual brain cells can greatly advance our understanding of the 
cell-type specific function of dystrophin in the brain and how the underlying cellular composition affects dystro-
phin function across brain regions.
The virtual lack of Dp260 and Dp116 expression confirms earlier hypotheses on the exclusive expression of 
these isoforms in the retina and peripheral nerves, respectively, despite a recent report indicating that Dp260 may 
be expressed in brain as well44. Based on the BrainSpan data, Dp140 is expressed mainly during the foetal stages of 
life across the brain, and at middle adulthood in few samples from the cerebellum and cortex. These results are in 
Figure 6. Dystrophin isoform co-expression networks and their associated GO-terms. Co-expression networks 
showing the top 25 positive correlating genes to the dystrophin isoforms Dp427, Dp140 and Dp71 + Dp40 
across development. Edges between nodes represent correlation strength (the thicker the line the more 
correlated the genes). Correlations to dystrophin isoforms are shown in red (not weighted). Genes are color-
coded according to their disease associations from DisGeNet. The bar plot shows the top terms enriched within 
the top 200 correlated genes. The vertical red line indicates the significance level (FDR-corrected P-value of 
<0.05).
www.nature.com/scientificreports/
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line with earlier results from foetal and adult human brain samples, where Western-blot analysis showed Dp140 
in the foetal brain but not in the adult brain21,32,33. Interestingly, the AHBA data indicates that DMD expression 
is low in the cerebellum relative to the rest of the brain. Based on our validation we observed high expression of 
Dp140 in the adult human cerebellum and much lower expression in the cortex, in contrast to the earlier obser-
vation from AHBA. Further analysis of the expression of the Dp140 TSS from the FANTOM5 data indicates that 
indeed Dp140 is expressed/present in the adult human cerebellum.
The Dp71 and Dp40 isoforms showed consistent expression throughout brain development. Although we 
could not differentiate between Dp71 and Dp40 isoforms because they share a first exon, the high expression level 
of the last exon (belonging to Dp71 and not Dp40) suggests some specificity for the high signal to Dp71.
Caution is needed when extrapolating our results to protein quantity, as our results represent RNA expres-
sion levels which is still several steps removed from the final protein product45. Also, in the current study, we 
analysed the variable expression patterns of the different dystrophin isoforms across brain areas and develop-
ment stages. Future work can determine the regulatory mechanisms responsible for these expression patterns. 
For instance, different isoforms might be regulated by different sets of transcription factors which can be dis-
covered through a motif analysis and validated using chromatin immune precipitation followed by sequencing 
(CHIP-seq) experiments.
Cerebellar dysfunction has been suggested to underlie deficits in reading and verbal working memory as 
well as playing an role in ASD which are important components of the DMD cognitive deficit46,47. Our results 
rather emphasize the amygdala, involved in emotion regulation, and the hippocampus, involved in memory, 
based on their high expression of DMD and the supporting evidence of memory and emotion deficits in DMD 
from animal and neuropsychological studies in humans5,26,48,49. Moreover, we show a relatively even distribution 
of DMD expression throughout the cortex, involved in higher-order cognitive functioning. This is well in line 
with magnetic resonance imaging (MRI) studies demonstrating global structural alteration with reduced grey 
matter volume all through the cortex and altered white matter microstructure also throughout the brain in DMD 
patients compared to healthy age-matched controls27,50.
Co-expression analysis indicates a strong association between the dystrophin isoforms and genes implicated 
in ASD and ID, which might explain the high comorbidity of these disorders in DMD and possibly BMD patients. 
Functional enrichment analysis of strongly co-expressed genes advocates different functions for the three groups 
of isoforms throughout development. Dp140 shows a stronger co-expression within the network compared to 
the networks for Dp427 and Dp71 + Dp40. This may be related to the higher expression of Dp140 early in devel-
opment. It could also be due to a physical link between the protein product of one of the neurodevelopmental 
disease genes to dystrophin. However, the protein domains within Dp140 largely overlap with those of the other 
dystrophin isoforms (with the exception of the N-terminal/actin binding domain which is specific to full length 
dystrophin). It is therefore unlikely that there are Dp140 specific protein interactions compared to Dp427 and 
Dp71, but it might be that there are cell-type specific interactions that are still undiscovered. The localization of 
Dp427 to the synaptic membrane in neurons with a function revolving around transmembrane transport and 
signal transmission further supports the proposed dystrophin-glycoprotein complex-like structure positioned 
in post-synaptic densities of GABA-ergic neurons in the brain14. Dp140, however, clearly shows a different role 
tailored towards axon guidance and transcription factor activity as well as neuron differentiation which are early 
neurodevelopmental processes. Absence of Dp140 may therefore lead to abnormal nervous system tract mor-
phology as proposed by the GO-terms which might explain the altered white matter microstructure detected by 
MRI27. The presence of Dp140 in later life is unexpected as the main functional terms relate to early neurodevel-
opment. However, transcription factor activity or chromatin modifications, which were also strongly associated, 
may suggest a role in generic transcription pathways. It is worth noting that mutations in genes involved in chro-
matin remodelling are strongly associated to ASD51.
The association of Dp71 + Dp40 signal transduction plus transmembrane receptor binding in relation to 
growth factors implies that the structural alterations thus far observed in the brains of patients missing Dp427 
and Dp14027 may be further aggravated in patients missing Dp71 and Dp40. Future studies on cerebral structural 
integrity in the absence of Dp71 and Dp40 can test this hypothesis. Interestingly, Dp71 + Dp40 were also associ-
ated with the cerebral vasculature and blood vessel development. Studies have shown altered cerebral blood flow 
in DMD, but the mouse models used in these studies did not have mutations that were predicted to affect Dp71 
of Dp4052.
Clinical trials for DMD include strategies that aim to restore functional dystrophin protein targeting tran-
script pre-mRNA splicing or translations53–57. In order to restore function of dystrophin in the brain, compounds 
need to cross the blood-brain-barrier (BBB), which is not the case for all. However, the implications of restoring 
dystrophin in the brain if they do cross the BBB are not clear, which argues that preclinical assessments and clin-
ical trials need to monitor the central nervous system.
Our results indicate that dystrophin isoforms play an important role in the development and function of the 
human brain. These findings advocate for the necessity to profile the expression of the dystrophin isoforms in 
post-mortem brain samples from people with dystrophinopathies in order to elucidate the transcriptional mech-
anisms underlying the behavioural and learning problems in DMD. This can greatly facilitate risk assessments of 
comorbid disorders and guide screening for early detection and targeted treatment. It also argues for the need of 
clinical trials to target and monitor the central nervous system.
Materials and Methods
BrainSpan developing human brain transcriptome. RNA-sequencing-derived exon-level expres-
sion data of the different isoforms of DMD was downloaded from the BrainSpan atlas of the developing human 
brain transcriptome28. RNA sequencing (RNA-seq) data was generated from 524 tissue samples collected 
from 42 post-mortem brains collected from neurologically unremarkable individuals spanning early pre-natal 
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development (8 post-conception weeks, PCW) to late adulthood (40 years of age). Samples were extracted using 
macro dissection from 8–16 regions per brain. Details of tissue acquisition and data processing can be found 
on the website (http://www.brainspan.org). Gene and exon annotation of the RNA-seq data was derived from 
Gencode version 10 (GRCh37 – Ensembl 65). The expression level of the exons was measured in RPKM (reads 
per kilobase of exon model per million mapped reads).
The DMD gene (Chromosome X: 31,115,794–33,357,558) data included 94 exons. There are however 79 exons 
in the well-known muscle dystrophin Dp427m (NM_004006.2). We therefore mapped the exon locations to 
the Dp427m exon annotation (Fig. 2). In this process, we found the values specific for the isoform first exons 
(which are not exons in Dp427m) and we found genomic coordinates that were mapping to a lymphocyte iso-
form (Dp427l). This isoform is no longer included in the latest release of the human genome (Gencode version 
21; GRCh38 – Ensemble 78), due to lack of evidence58. As such, we excluded these exon coordinates from further 
analysis.
Adult human brain expression data. Spatial gene expression data from six adult human brains was 
obtained from the Allen Human Brain Atlas database (AHBA)59. Samples were collected from post-mortem 
brains from five males and one female between 24 and 57 years of age (mean age 42), with no known psycho-
pathologies, by either manual macrodissection (cortical and some subcortical structures) or by laser-based 
microdissection (subcortical and brainstem areas). For each brain, RNA was extracted from 363 to 946 different 
samples per brain (3702 samples in total) and measured on custom Agilent microarrays containing the 4 × 44K 
Agilent Whole Human Genome probes as well as an additional 16,000 custom probes. For genes with two probes, 
the one with the highest variance was selected. For genes with at least three probes, the connectivity of each 
probe was calculated (sum of the Pearson correlations to all other probes, measured per brain and then aver-
aged) and the one with the highest connectivity was selected. Expression data of the 19,991 genes was z-score 
normalized per brain. The expression of the DMD gene was measured using six probes, of which A_24_P185854 
(NM_004023.1) has the highest connectivity and hence was used for further analysis. This probe is located at the 
distal part of the gene and captures the Dp71, Dp116, Dp140, Dp260, and Dp427 isoforms (all except Dp40). 
For visualization, z-score values of the DMD gene expression were mapped to anatomical atlas images acquired 
from the Allen Human Brain Atlas59. The following acronyms are indicated in Fig. 3A; BG: Basal ganglia, BL: 
Basolateral nucleus, BM: Basomedial nucleus, BL: Biventral lobule, CA1: CA1 region of the hippocampus, CA2: 
CA2 region of the hippocampus, CA3: CA3 region of the hippocampus, Cig: Caudal granular insular cortex, 
CE: Central nuclear group, DG: Dentate gyrus, DN: Dentate nucleus, Fas: Fastigial nucleus, Glo: Globose, ICx: 
Insular neocortex, LEC: Lateral entorhinal cortex, La: Lateral nucleus, MEC: Medial lateral entorhinal cortex, 
MCC: Midcingulate gyrus, MTC: Midlateral temporal cortex, OCx: Occipital neocortex, PCx: Parietal neocor-
tex, PCC: Posterior cingulate cortex, CoP: Posterior cortical nucleus, IPC: Posteroventral parietal cortex, IPC: 
Posteroventral parietal cortex, PMC: Premotor cortex, A1C: Primary auditory cortex, M1C: Primary motor cor-
tex, S1C: Primary somatosensory cortex, SL: semilunal lobule, SsC: Subcentral cortex, Sub: Subicular cortex, 
SLTC: Superolateral temporalcortex, TO: Tonsilla, VLTC: Ventrolateral temporal neocortex.
Co-expression Analysis. To characterize the functional association of the DMD gene in the adult human 
brain, we calculated the spatial correlation (Pearson’s) between each gene in the AHBA (19,991 genes) and the 
DMD gene using all samples concatenated from the six donors (3,702 samples). Genes were ranked based on the 
correlations in a descending order. To assess the functional association of the different dystrophin isoforms across 
development, we calculated the spatial-temporal correlation (Pearson’s) between each exon in the BrainSpan 
dataset (241,690 exons) and the exons that are specific to each of the three dystrophin isoforms groups: exon 2 
for full-length Dp427, isoform specific exons located in intron 44 for Dp140 and intron 62 for Dp71 + Dp40 with 
respect to Dp427m nomenclature. These isoforms were selected because virtually all DMD patients have muta-
tions affecting Dp427c, Dp427m and Dp427p60. A proportion of patients additionally cannot produce Dp140. A 
small number of patients cannot produce any isoforms, including the shortest Dp71 and Dp40. For each isoform 
group, we ranked all exons in a descending order based on correlation. To get a ranked gene list, each gene was 
assigned the rank of its most correlated exon. For each gene set, functional enrichment analysis was performed 
on the top 1% (most positively correlated). Functional enrichment analysis was performed using ToppGene61. 
We returned all terms enriched at a false discovery rate (FDR)-corrected q-value of 0.05 from the categories: GO 
Molecular Function, GO Biological Process, GO Cellular Component, Human Phenotype, Mouse Phenotype, 
and Pathway.
Disease gene sets overrepresentation. Enrichment analysis of disease-related gene sets was performed 
using a two-sided Wilcoxon rank sum test (Mann-Whitney U-test). For each list of all genes ranked based on 
their co-expression with dystrophin expression we used the rank sum test to assess the significance of the ranks 
of each disease gene set. To control the FDR, we corrected for multiple testing using the Benjamini-Hochberg 
method62. In case of the adult human brain we tested the set of 19,991 genes, ranked based on their correlation 
to the DMD gene across all samples (Pearson’s correlation). Similarly, for the BrainSpan developing human brain 
transcriptome we tested three sets of 21,164 genes ranked based on their co-expression with the exons corre-
sponding to the three dystrophin isoforms: Dp71 + Dp40, Dp140 and Dp427.
We tested for the enrichment of five disease-related gene sets. The ASD-ID list contained 827 genes harbour-
ing de novo mutations from four ASD63–66 and two ID67,68 exome sequencing studies. The ASD-ID was retrieved 
from69. The SFARI ASD list contained 706 genes associated to ASD using manual curation of published scientific 
literature from the Simons Foundation Autism Research Initiative (SFARI) AutDB database70. The list includes 
candidate genes implicated by common variant association, candidate gene studies, genes within ASD-associated 
copy number variants (CNV), and genes implicated in syndromic forms of ASD. Lists of genes related to ADD, 
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OCD and dyslexia were retrieved from DisGeNet v3.0, a database that integrates human gene-disease associations 
from various expert curated sources and text-mining of literature40.
Fantom5 data. We used the FANTOM5 samples ontology and the linked data version of FANTOM5 
data, which was exposed as nanopublications36,37. We queried the FANTOM5 data to get all transcription start 
sites which are overlapping with the first exons of Dp427c, Dp427m, Dp427p, Dp260, Dp140, Dp116, and 
Dp70 + Dp41. We selected only samples belonging to the cerebral cortex, hippocampus, amygdala and cere-
bellum brain regions. Further, we removed samples pooled from multiple donors since they spanned a wide age 
range, which could dilute the expression of a transcription start site (TSS) varied through development. Our 
analysis resulted in 25 TSSs across eight samples (Supplementary Table 3).
Epigenetic data. Data from the Roadmap Epigenomics Consortium38 was visualized using the WashU 
EpiGenome Browser v40.0.071. We visualized only the track corresponding to active TSS chromatin state. Details 
of the 23 selected samples are in Supplementary Table 7.
Validation using ex vivo qPCR. Frozen tissue samples from a 51-year-old male non-demented control 
brain of the anterior orbital gyrus and cerebellum were obtained (post-mortem delay: 07:45 hr; pH 7.05, stored in 
cryovial at −80°). The brain samples were obtained from The Netherlands Brain Bank, Netherlands Institute for 
Neuroscience, Amsterdam (open access: www.brainbank.nl). All Material has been collected from donors for or 
from whom a written informed consent for a brain autopsy and the use of the material and clinical information 
for research purposes had been obtained by the Netherlands Brain Bank.
Mice used in this study were bred in the Experimental Animal Facility of the Leiden University Medical 
Center and kept in individually ventilated cages with 12 hours of light/dark cycles at 20.5 °C and had ad libitum 
access to standard RM3 chow (SDS, Essex, UK) and water. All experiments were approved by and performed 
following the guidelines of the Animal Experiment Committee of the Leiden University Medical Center. Care 
was taken to limit the burden and distress for the animals as much as possible. The cortex and cerebellum of two 
24-week-old female C57BL/10cSnJ wildtype mice were isolated and snap frozen on dry ice. For total RNA isola-
tion, tissue was disrupted in tubes with MagNALyser Green Beads (Roche Diagnostics, The Netherlands) with 
TriPure Isolation Reagent (Roche Diagnostics). Isolation was performed with chloroform, and RNA was precip-
itated with isopropanol. The NucleoSpin RNA II kit including DNase digestion (Bioke, Leiden, The Netherlands) 
was used for RNA purification. RNA quality and concentrations were checked with the NanoDrop. RNA (1 µg) 
was used for cDNA synthesis with random hexamer primers. Expression of Dp427c, Dp427p, Dp140 and Dp71 
(primer sequences available in Supplementary Table 8) was determined by SYBR Green-based real-time quan-
titative PCR (95 °C for 10 s, 60 °C for 30 s, and 72 °C for 20 s, 45 cycles followed by melting curve analysis) on the 
Roche LightCycler 480 (Roche Diagnostics). Samples were tested in triplo on a 384 wells plate and H2O and –RT 
controls were included for all primers. Housekeeping gene RPL22 was used as a reference gene. Primer efficiencies 
were determined and analysis was performed with LinREgPCR72.
Data availability. All data generated or analysed during this study are included in this published article (and 
its Supplementary Information files).
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